Patents by Inventor James Q. Oeswein
James Q. Oeswein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110230408Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.Type: ApplicationFiled: June 1, 2011Publication date: September 22, 2011Applicant: Genentech, Inc.Inventors: Barbara H. O'Connor, James Q. Oeswein
-
Publication number: 20090163419Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.Type: ApplicationFiled: January 15, 2009Publication date: June 25, 2009Applicant: Genentech, Inc.Inventors: Barbara H. O'Connor, James Q. Oeswein
-
Patent number: 7186686Abstract: A composition is disclosed that comprises a mixture of polypeptides of opposite charge and an excipient selected from the group consisting of arginine, lysine, glutamic acid, sodium dodecyl sulfate, beta-hydroxy cyclodextrin, and beta-cyclodextrin sulfobutyl ether.Type: GrantFiled: May 6, 2003Date of Patent: March 6, 2007Assignee: Genentech, Inc.Inventors: James Q. Oeswein, John R. Smikahl, Sharon X. Wang, Douglas A. Yeung
-
Patent number: 6991790Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of antibody not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.5 to about 6.0, a surfactant and a polyol is described, along with uses for such a formulation.Type: GrantFiled: November 28, 2000Date of Patent: January 31, 2006Assignee: Genentech, Inc.Inventors: Xanthe M. Lam, James Q. Oeswein, Boonsri Ongpipattanakul, Zehra Shahrokh, Sharon X. Wang, Robert P. Weissburg, Rita L. Wong
-
Publication number: 20030195142Abstract: A composition is disclosed that comprises a mixture of polypeptides of opposite charge and an excipient selected from the group consisting of arginine, lysine, glutamic acid, sodium dodecyl sulfate, beta-hydroxy cyclodextrin, and beta-cyclodextrin sulfobutyl ether.Type: ApplicationFiled: May 6, 2003Publication date: October 16, 2003Inventors: James Q. Oeswein, John R. Smikahl, Sharon X. Wang, Douglas A. Yeung
-
Patent number: 6559122Abstract: A composition is disclosed that comprises a mixture of polypeptides of opposite charge and an excipient selected from the group consisting of arginine, lysine, glutamic acid, sodium dodecyl sulfate, beta-hydroxy cyclodextrin, and beta-cyclodextrin sulfobutyl ether.Type: GrantFiled: March 30, 2000Date of Patent: May 6, 2003Assignee: Genentech, Inc.Inventors: James Q. Oeswein, John R. Smikahl, Sharon X. Wang, Douglas A. Yeung
-
Publication number: 20030013653Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.Type: ApplicationFiled: July 1, 2002Publication date: January 16, 2003Applicant: Genentech, Inc.Inventors: Barbara H. O'Connor, James Q. Oeswein
-
Patent number: 6448225Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated methods for preparing, storing, and using such formulations.Type: GrantFiled: June 25, 1999Date of Patent: September 10, 2002Assignee: Genentech, Inc.Inventors: Barbara H. O'Connor, James Q. Oeswein
-
Publication number: 20010007858Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.Type: ApplicationFiled: June 25, 1999Publication date: July 12, 2001Applicant: GENENTECH, INC.Inventors: BARBARA H. O'CONNOR, JAMES Q. OESWEIN
-
Patent number: 6171586Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.5 to about 6.0, a surfactant and a polyol is described, along with uses for such a formulation.Type: GrantFiled: June 12, 1998Date of Patent: January 9, 2001Assignee: Genentech, Inc.Inventors: Xanthe M. Lam, James Q. Oeswein, Boonsri Ongpipattanakul, Zahra Shahrokh, Sharon X. Wang, Robert P. Weissburg, Rita L. Wong
-
Patent number: 5981485Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.Type: GrantFiled: July 14, 1997Date of Patent: November 9, 1999Assignee: Genentech, Inc.Inventors: Barbara H. O'Connor, James Q. Oeswein
-
Patent number: 5783556Abstract: Formulations containing NPH insulin are useful for treating hyperglycemic disorders, such as diabetes, in a mammal in need of treatment. One such formulation, which is preferably administered parenterally, more preferably by injection, comprises IGF-I and NPH insulin, in amounts of from or about 1 to 10 mg IGF-I and from or about 0.2 to 2 mg NPH insulin in a pharmaceutically acceptable carrier. Another such formulation comprises IGF-I and NPH insulin in an acetic acid salt buffer. Still another formulation comprises IGF-I and NPH insulin in a weight ratio of NPH insulin to IGF-I of from or about 10:1 to 1:50 (w/w), from or about 0.05 to 0.3M of an osmolyte, from or about 0.1 to 10 mg/mL of a stabilizer, and from or about 5 to 100 mM of a buffer at from or about pH 5 to 7. A still further composition comprises NPH insulin in an acetic acid salt buffer.Type: GrantFiled: August 13, 1996Date of Patent: July 21, 1998Assignee: Genentech, Inc.Inventors: Ross G. Clark, James Q. Oeswein, Douglas A. Yeung
-
Patent number: 5763394Abstract: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.Type: GrantFiled: September 14, 1993Date of Patent: June 9, 1998Assignee: Genentech, Inc.Inventors: Barbara H. O'Connor, James Q. Oeswein
-
Patent number: 5681814Abstract: A formulation for IGF-I is disclosed that is useful in treating hyperglycemic disorders and, in combination with growth hormone, in enhancing growth of a mammal. Also disclosed is a process for preparing a formulation of growth hormone and IGF-I from the IGF-I formulation. The IGF-I formulation comprises about 2-20 mg/ml of IGF-I, about 2-50 mg/ml of an osmolyte, about 1-15 mg/ml of a stabilizer, and a buffered solution at about pH 5-5.5, optionally with a surfactant.Type: GrantFiled: June 4, 1993Date of Patent: October 28, 1997Assignee: Genentech, Inc.Inventors: Ross G. Clark, Douglas A. Yeung, James Q. Oeswein
-
Patent number: 5597802Abstract: A formulation for IGF-I is disclosed that is useful in treating hyperglycemic disorders and, in combination with growth hormone, in enhancing growth of a mammal. Also disclosed is a process for preparing a formulation of growth hormone and IGF-I from the IGF-I formulation. The IGF-I formulation comprises about 2-20 mg/ml of IGF-I, about 2-50 mg/ml of an osmolyte, about 1-15 mg/ml of a stabilizer, and a buffered solution at about pH 5-5.5, optionally with a surfactant.Type: GrantFiled: June 2, 1995Date of Patent: January 28, 1997Assignee: Genentech, Inc.Inventors: Ross G. Clark, Douglas A. Yeung, James Q. Oeswein
-
Patent number: 5472022Abstract: An injection pen apparatus (30) for medicament injection including a medicament cartridge assembly (31) formed to receive and contain a medicament therein. A holding sleeve (34) is provided which is dimensioned to receive the medicament cartridge assembly (31) therein which mates with a solution transfer device (35) including an axially movable displacement rod (36). The injection pen apparatus (30) further includes a coupling mechanism (37) removably coupling the solution transfer device (35) to both a plunger (32) slidably movable in the cartridge (33) and to the holding sleeve (34). A sleeve mounting assembly (40) of the coupling mechanism (37) removably mounts the coupling mechanism to the holding sleeve (34).Type: GrantFiled: November 2, 1993Date of Patent: December 5, 1995Assignee: Genentech, Inc.Inventors: Peter Michel, Robert S. Freeman, James Q. Oeswein
-
Patent number: 5374620Abstract: A combined formulation for IGF-I and growth hormone (GH) is useful for enhancing growth of a mammal. This formulation, which may be administered by infusion or injection to enhance growth, comprises IGF-I and GH, each in amounts of 0.1 to 100 mg/ml, in a pharmaceutically acceptable carrier at a pH of about 5-6 containing a surfactant, wherein the amounts of IGF-I and GH in the composition are effective to promote growth of a mammal more than an equivalent dose of IGF-I or GH alone, and wherein the weight ratio of IGF-I to GH in the composition ranges from 0.002:1 to 240:1.Type: GrantFiled: June 4, 1993Date of Patent: December 20, 1994Assignee: Genentech, Inc.Inventors: Ross G. Clark, Michael J. Cronin, Douglas A. Yeung, James Q. Oeswein
-
Patent number: 5096885Abstract: A stable pharmaceutically acceptable formulation containing human growth hormone, glycine, mannitol, a buffer, and optionally, a non-ionic surfactant is disclosed. The formulation contains human growth-hormone: glycine in 1:50-200 molar ratios. Also disclosed are associated means and methods for preparing and using such formulations.Type: GrantFiled: April 15, 1988Date of Patent: March 17, 1992Assignee: Genentech, Inc.Inventors: Rodney Pearlman, James Q. Oeswein